المؤلفون: Solves, Pilar, Bataller, Ana, Gálvez, Ana Belén, Asensi Cantó, Pedro, Santiago, Marta, Moreno, María José, Gómez-Seguí, Inés, de la Rubia, Javier

المصدر: Hemato; Jun2024, Vol. 5 Issue 2, p109-114, 6p

مستخلص: Background: Selective IgA deficiency (IgA-D) has been historically considered a high-risk entity for developing allergic/anaphylactic reactions after blood transfusion (AATRs). However, it has been suggested that the IgA-D-related anaphylactic transfusion reaction is not evidence-based. Methods: We conducted three different approaches to collect evidence about epidemiology, AATRs, and transfusion management of patients with IgA-D at La Fe University Hospital. Firstly, we analysed the prevalence of IgA-D in a population of patients diagnosed with acute leukaemia, The second approach consisted of collecting transfusion data from IgA-D patients. Finally, we reviewed the IgA levels of patients recorded in the hemovigilance system suffering an AATR. Results: IgA-D prevalence was 1 in 334 patients. At least one blood component was transfused to 23 patients diagnosed with IgA-D. Plasma was transfused to eight IgA-D patients, while six patients received red blood cells, platelets, and plasma. No adverse reactions were reported in any patient. AATRs occurred in 325 men and 264 women with a median age of 52 years. Severe reactions occurred in 56 patients (1/14,520 components). Mean IgA levels were 215 mg/dL (4–5570) for mild reactions and 214 mg/dL (14–824) for severe reactions (p = ns). Washed platelets were administered to two patients who developed severe and repeated AATRs. Both had normal IgA levels. Conclusions: Since the AATRs related to IgA-D are extremely low, as reported in current hemovigilance systems, IgA-D should not be considered a high-risk entity to develop AATRs. On the contrary, our findings support standard transfusion management of IgA-D patients. [ABSTRACT FROM AUTHOR]

: Copyright of Hemato is the property of MDPI and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

المؤلفون: Seguí, Inés Gómez, Mingot Castellano, María Eva, Izquierdo, Cristina Pascual, de la Rubia, Javier

المصدر: Expert Review of Hematology; Jan-Mar2024, Vol. 17 Issue 1-3, p9-25, 17p

المؤلفون: Ríos-Tamayo, Rafael, Soler, Juan Alfons, García-Sánchez, Ricarda, Pérez Persona, Ernesto, Arnao, Mario, García-Guiñón, Antoni, Domingo, Abel, González-Pardo, Miriam, de la Rubia, Javier, Mateos, María Victoria

المصدر: Hematology; Dec2023, Vol. 28 Issue 1, p1-11, 11p

مصطلحات موضوعية: MULTIPLE myeloma, MONOCLONAL antibodies, CLINICAL trials, PROGRESSION-free survival

مستخلص: To describe the incorporation of monoclonal antibodies (mAb) in real-world (RW) practice for the treatment of patients with relapsed refractory multiple myeloma (RRMM) in a setting with other treatment alternatives. This was an observational, multicenter, ambispective study of RRMM treated with or without a mAb. A total of 171 patients were included. For the group treated without mAb, the median (95% CI) progression-free survival (PFS) to relapse was 22.4 (17.8-27.0) months; partial response or better (≥PR) and complete response or better (≥CR) was observed in 74.1% and 24.1% of patients, respectively; and median time to first response in first relapse was 2.0 months and in second relapse was 2.5 months. For the group of patients treated with mAb in first or second relapse, the median PFS was 20.9 (95% CI, could not be evaluated) months; the ≥ PR and ≥ CR rates were 76,2% and 28.6%, respectively; and the median time to first response in first relapse was 1.2 month and in second relapse was 1.0 months. The safety profiles for the combinations were consistent with those expected. The incorporation of mAb in RW practice for the treatment of RRMM has shown good quality and speed of response with a similar safety profile shown in randomized clinical trials. [ABSTRACT FROM AUTHOR]

: Copyright of Hematology is the property of Taylor & Francis Ltd and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

المؤلفون: Cárdenas, María C., García-Sanz, Ramón, Puig, Noemí, Pérez-Surribas, David, Flores-Montero, Juan, Ortiz-Espejo, María, de la Rubia, Javier, Cruz-Iglesias, Elena

المصدر: Clinical Chemistry & Laboratory Medicine; Nov2023, Vol. 61 Issue 12, p2115-2130, 16p

مصطلحات موضوعية: MONOCLONAL gammopathies, MONOCLONAL antibodies, IMMUNOGLOBULIN light chains, BONE marrow examination, BLOOD transfusion, HEMATOLOGY

مستخلص: Monoclonal gammopathies (MG) are characterized by the proliferation of plasma cells that produce identical abnormal immunoglobulins (intact or some of their subunits). This abnormal immunoglobulin component is called monoclonal protein (M-protein), and is considered a biomarker of proliferative activity. The identification, characterization and measurement of M-protein is essential for the management of MG. We conducted a systematic review of the different tests and measurement methods used in the clinical laboratory for the study of M-protein in serum and urine, the biochemistry and hematology tests necessary for clinical evaluation, and studies in bone marrow, peripheral blood and other tissues. This review included literature published between 2009 and 2022. The paper discusses the main methodological characteristics and limitations, as well as the purpose and clinical value of the different tests used in the diagnosis, prognosis, monitoring and assessment of treatment response in MG. Included are methods for the study of M-protein, namely electrophoresis, measurement of immunoglobulin levels, serum free light chains, immunoglobulin heavy chain/light chain pairs, and mass spectrometry, and for the bone marrow examination, morphological analysis, cytogenetics, molecular techniques, and multiparameter flow cytometry. [ABSTRACT FROM AUTHOR]

: Copyright of Clinical Chemistry & Laboratory Medicine is the property of De Gruyter and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

المؤلفون: Cárdenas, María C., García-Sanz, Ramón, Puig, Noemí, Pérez-Surribas, David, Flores-Montero, Juan, Ortiz-Espejo, María, De la Rubia, Javier, Cruz-Iglesias, Elena

المصدر: Clinical Chemistry & Laboratory Medicine; Nov2023, Vol. 61 Issue 12, p2131-2142, 12p

مصطلحات موضوعية: MONOCLONAL gammopathies, BLOOD transfusion, PATHOLOGICAL laboratories, CLINICAL pathology, HEMATOLOGY, MONOCLONAL antibodies

مستخلص: Monoclonal gammopathies (MG) are a group of clinical entities characterized by the clonal expansion of monoclonal immunoglobulin (M-protein) secreting plasma cells (PC). This document presents the consensus recommendations of the Spanish Society of Laboratory Medicine (SEQC^ML) and the Spanish Society of Hematology and Hemotherapy (SEHH) for the study of MG. The recommendations were established based on scientific evidence and the opinion of experts in MG from the clinical laboratory and clinical hematology fields. Recommendations are proposed for the diagnosis of MG and for patient follow-up according to the type of MG and whether or not the patient is undergoing treatment, and to monitor the disease stability, response to therapy and disease progression. With respect to the diagnosis, we describe the most recent criteria and classification established by the International Myeloma Working Group (IMWG) for multiple myeloma (MM), smoldering MM, monoclonal gammopathy of undermined significance (MGUS) and other related entities. Indications are given about the analytical requirements and application of the different serum and urine laboratory tests (study, detection, identification and measurement of M-protein) and the bone marrow study. Recommendations on the clinical laboratory results report model are established to harmonize and ensure that all relevant information is available, including its content, expression, and interpretive comments. [ABSTRACT FROM AUTHOR]

: Copyright of Clinical Chemistry & Laboratory Medicine is the property of De Gruyter and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

المؤلفون: de la Rubia, Javier^1,2 (AUTHOR) delarubia_jav@gva.es, Alonso, Rafael³ (AUTHOR), Clavero, María Esther⁴ (AUTHOR), Askari, Elham⁵ (AUTHOR), García, Alfonso⁶ (AUTHOR), Antón, Cristina⁷ (AUTHOR), Fernández, Margarita⁸ (AUTHOR), Escalante, Fernando⁹ (AUTHOR), García, Ana¹⁰ (AUTHOR), Rios-Tamayo, Rafael¹¹ (AUTHOR), Conesa, Venancio¹² (AUTHOR), Bermúdez, María Arancha¹³ (AUTHOR), Merchán, Beatriz¹⁴ (AUTHOR), Velasco, Alberto E.¹⁵ (AUTHOR), Blanchard, María Jesús¹⁶ (AUTHOR), Sampol, Antonia¹⁷ (AUTHOR), Gainza, Eukene¹⁸ (AUTHOR), Hernández, Prisma Montserrat¹⁹ (AUTHOR), Alegre, Adrián²⁰ (AUTHOR)

المصدر: Cancers. Jun2023, Vol. 15 Issue 11, p2964. 13p.

مصطلحات موضوعية: *THERAPEUTIC use of immunoglobulins, *RESEARCH, *SCIENTIFIC observation, *CONFIDENCE intervals, *IMMUNOGLOBULINS, *OPTIC nerve diseases, *CANCER relapse, *INVESTIGATIONAL drugs, *CELL receptors, *RETROSPECTIVE studies, *ACQUISITION of data, *TREATMENT effectiveness, *COMPARATIVE studies, *MEDICAL records, *DESCRIPTIVE statistics, *MULTIPLE myeloma, *PROGRESSION-free survival, *PATIENT safety, *OVERALL survival, *DISEASE risk factors

مصطلحات جغرافية: SPAIN

مستخلص: Simple Summary: Patients with multiple myeloma (MM) who become refractory to three or more lines of therapy (RRMM patients) have few valid therapeutic alternatives. Among them, drugs directed against the BCMA antigen expressed in plasma cells are very appealing. Belantamab-mafodotin (belamaf) is the first antibody-drug conjugate against BCMA ready for clinical use. In this paper, we report the Spanish experience of belamaf monotherapy in 156 patients with RRMM. The overall response rate was 41.8%, with 39.8% of patients achieving a partial response or better. Median progression-free survival was 3.61 months, but interestingly, it increased to 14.47 months in patients achieving a minimal response or better. Treatment was well tolerated, ocular events being the most reported toxicity (87.9%; grade ≥ 3, 33.7%), but only two patients discontinued treatment due to side effects. Overall, our results confirm the safety and efficacy of belamaf in this poor prognosis subset of patients. Belantamab-mafodotin (belamaf) is a novel antibody-drug conjugate targeting B-cell maturation antigen that showed anti-myeloma activity in patients with relapsed and refractory multiple myeloma (RRMM). We performed an observational, retrospective, and multicenter study aimed to assess the efficacy and safety of single-agent belamaf in 156 Spanish patients with RRMM. The median number of prior therapy lines was 5 (range, 1–10), and 88% of patients were triple-class refractory. Median follow-up was 10.9 months (range, 1–28.6). The overall response rate was 41.8% (≥CR 13.5%, VGPR 9%, PR 17.3%, MR 2%). The median progression-free survival was 3.61 months (95% CI, 2.1–5.1) and 14.47 months (95% CI, 7.91–21.04) in patients achieving at least MR (p < 0.001). Median overall survival in the entire cohort and in patients with MR or better was 11.05 months (95% CI, 8.7–13.3) and 23.35 (NA-NA) months, respectively (p < 0.001). Corneal events (87.9%; grade ≥ 3, 33.7%) were the most commonly adverse events, while thrombocytopenia and infections occurred in 15.4% and 15% of patients, respectively. Two (1.3%) patients discontinued treatment permanently due to ocular toxicity. Belamaf showed a noticeably anti-myeloma activity in this real-life series of patients, particularly among those achieving MR or better. The safety profile was manageable and consistent with prior studies. [ABSTRACT FROM AUTHOR]

المؤلفون: Burgos, Leire, Tamariz-Amador, Luis-Esteban, Puig, Noemi, Cedena, Maria-Teresa, Guerrero, Camila, Jelínek, Tomas, Johnson, Sarah, Milani, Paolo, Cordon, Lourdes, Perez, Jose J., Lasa, Marta, Termini, Rosalinda, Oriol, Albert, Hernandez, Miguel-Teodoro, Palomera, Luis, Martinez-Martinez, Rafael, de la Rubia, Javier, de Arriba, Felipe, Rios, Rafael, Gonzalez, Maria-Esther

المصدر: Journal of Clinical Oncology; 6/1/2023, Vol. 41 Issue 16, p3019-3031, 13p

المؤلفون: Solves, Pilar, Marco-Ayala, Javier, Sanz, Miguel Ángel, Gómez-Seguí, Inés, Balaguer-Roselló, Aitana, Facal, Ana, Villalba, Marta, Montoro, Juan, Sanz, Guillermo, de la Rubia, Javier, Sanz, Jaime

المصدر: Journal of Clinical Medicine; May2023, Vol. 12 Issue 10, p3467, 10p

مصطلحات موضوعية: HEMATOPOIETIC stem cell transplantation, CORD blood transplantation, BLOOD transfusion

مستخلص: Introduction: Transfusion plays a main role in supportive treatment for patients who receive an allogeneic hematopoietic stem cell transplantation (HSCT). In this study, we compare the transfusion requirements of patients undergoing different modalities of HSCT according to different time periods. The objective is to assess the evolution of HSCT transfusion requirements over time, from a single institution. Methods: The clinical charts and transfusion records of patients who underwent HSCT of different modalities at La Fe University Hospital during a twelve-year period were reviewed (2009–2020). For analysis, we divided the overall time into three periods: 1 from 2009 to 2012, 2 from 2013 to 2016 and 3 from 2017 to 2020. The study included 855 consecutive adult HSCT: 358 HLA-matched related donors (MRD), 134 HLA-matched unrelated donors (MUD), 223 umbilical cord blood transplantation (UCBT) and 140 haploidentical transplants (Haplo-HSCT). Results: There were no significant differences in RBC and PLT requirements or transfusion independence among the three time periods for MUD and Haplo-HSCT. However, the transfusion burden increased significantly for MRD HSCT during the 2017–2020 period. Conclusion: despite HSCT modalities having evolved and changed over time, overall transfusion requirements have not significantly decreased and continue to be a cornerstone of transplantation-supportive care. [ABSTRACT FROM AUTHOR]

: Copyright of Journal of Clinical Medicine is the property of MDPI and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

المؤلفون: Wong, Sandy W., Bar, Noffar, Victoria Mateos, María, Ribas, Paz, Hansson, Markus, Paris, Laura, Hofmeister, Craig, Rodriguez‐Otero, Paula, Aranzazu Bermúdez, Maria, Santoro, Armando, Yee, Andrew J., Creignou, Maria, Encinas, Cristina, Cerchione, Claudio, de la Rubia, Javier, Oriol, Albert, Ferstl, Barbara, Besemer, Britta, Chen, Jinjie, Chung, Alexander

المصدر: HemaSphere; 2023 Supplement 3, Vol. 7, p1-3, 3p

المؤلفون: Dimopoulos, Meletios A., Moreau, Philippe, Augustson, Bradley, Castro, Nelson, Pika, Tomas, Delimpasi, Sosana, De la Rubia, Javier, Maiolino, Angelo, Reiman, Tony, Martinez‐Lopez, Joaquin, Martin, Thomas, Mikhael, Joseph, Yong, Kwee, Risse, Marie‐Laure, Asset, Gaelle, Marion, Sylvia, Hajek, Roman

المصدر: American Journal of Hematology; Jan2023, Vol. 98 Issue 1, pE15-E19, 5p